 Randall Meacham
Concepts (363)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infertility, Male | 13 | 2013 | 73 | 1.700 |
Why?
| | Ejaculation | 6 | 2006 | 12 | 0.990 |
Why?
| | Testis | 8 | 2012 | 163 | 0.910 |
Why?
| | Varicocele | 7 | 2011 | 10 | 0.850 |
Why?
| | Spermatozoa | 5 | 2007 | 109 | 0.840 |
Why?
| | Prostatic Neoplasms | 14 | 2012 | 978 | 0.730 |
Why?
| | Oligospermia | 5 | 2013 | 13 | 0.660 |
Why?
| | Azoospermia | 3 | 2013 | 10 | 0.610 |
Why?
| | Vas Deferens | 3 | 2006 | 11 | 0.490 |
Why?
| | Reproduction | 3 | 2006 | 207 | 0.480 |
Why?
| | Sperm Count | 5 | 2004 | 20 | 0.460 |
Why?
| | Urology | 3 | 2019 | 64 | 0.430 |
Why?
| | Hypogonadism | 3 | 2013 | 90 | 0.420 |
Why?
| | Penis | 3 | 2012 | 32 | 0.420 |
Why?
| | Clomiphene | 1 | 2013 | 15 | 0.400 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2013 | 36 | 0.390 |
Why?
| | Erectile Dysfunction | 3 | 2012 | 38 | 0.350 |
Why?
| | Diphosphonates | 1 | 2011 | 68 | 0.330 |
Why?
| | Testosterone | 3 | 2013 | 419 | 0.330 |
Why?
| | Apoptosis | 3 | 2004 | 2430 | 0.320 |
Why?
| | Male | 58 | 2021 | 72406 | 0.320 |
Why?
| | Oxalates | 4 | 2012 | 11 | 0.320 |
Why?
| | Fertility | 2 | 2006 | 168 | 0.310 |
Why?
| | Testicular Neoplasms | 3 | 2006 | 113 | 0.300 |
Why?
| | Ejaculatory Ducts | 4 | 2005 | 4 | 0.300 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 732 | 0.300 |
Why?
| | Electric Stimulation | 3 | 2005 | 276 | 0.290 |
Why?
| | Urinary Bladder | 3 | 2019 | 194 | 0.280 |
Why?
| | Genetic Therapy | 2 | 2008 | 313 | 0.280 |
Why?
| | Potassium Channels, Tandem Pore Domain | 2 | 2019 | 14 | 0.280 |
Why?
| | Autonomic Dysreflexia | 1 | 2007 | 4 | 0.260 |
Why?
| | Prostate | 1 | 2008 | 158 | 0.260 |
Why?
| | Physical Stimulation | 1 | 2007 | 68 | 0.260 |
Why?
| | Vibration | 1 | 2007 | 71 | 0.250 |
Why?
| | Spermatogenesis | 4 | 2002 | 91 | 0.250 |
Why?
| | Perineum | 1 | 2006 | 37 | 0.250 |
Why?
| | Penile Induration | 1 | 2006 | 2 | 0.250 |
Why?
| | Antineoplastic Agents | 2 | 2011 | 2197 | 0.250 |
Why?
| | Vasovasostomy | 1 | 2006 | 1 | 0.240 |
Why?
| | Inguinal Canal | 1 | 2006 | 11 | 0.240 |
Why?
| | Hernia, Inguinal | 2 | 2006 | 43 | 0.240 |
Why?
| | Genital Diseases, Male | 2 | 1996 | 17 | 0.240 |
Why?
| | Semen Preservation | 2 | 2004 | 3 | 0.240 |
Why?
| | Semen | 3 | 2002 | 23 | 0.240 |
Why?
| | Humans | 64 | 2022 | 144957 | 0.230 |
Why?
| | Health Expenditures | 1 | 2007 | 194 | 0.230 |
Why?
| | Interferon-alpha | 1 | 2006 | 197 | 0.220 |
Why?
| | Calcium Channel Blockers | 1 | 2006 | 165 | 0.220 |
Why?
| | Anal Canal | 1 | 2005 | 102 | 0.220 |
Why?
| | Cost of Illness | 1 | 2007 | 321 | 0.210 |
Why?
| | Cloning, Organism | 1 | 2004 | 7 | 0.210 |
Why?
| | Bioethical Issues | 1 | 2004 | 8 | 0.210 |
Why?
| | Cryptorchidism | 1 | 2004 | 17 | 0.210 |
Why?
| | Psychology, Adolescent | 1 | 2004 | 63 | 0.210 |
Why?
| | Aging | 5 | 2013 | 1966 | 0.200 |
Why?
| | Vasectomy | 1 | 2003 | 3 | 0.200 |
Why?
| | Spinal Cord Injuries | 1 | 2007 | 241 | 0.200 |
Why?
| | Tissue and Organ Harvesting | 1 | 2003 | 73 | 0.190 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2003 | 30 | 0.190 |
Why?
| | Matrix Metalloproteinase 9 | 4 | 2012 | 132 | 0.190 |
Why?
| | Sperm Motility | 3 | 1998 | 35 | 0.190 |
Why?
| | Pain Management | 1 | 2006 | 405 | 0.190 |
Why?
| | Surgical Mesh | 1 | 2002 | 50 | 0.180 |
Why?
| | Cryopreservation | 2 | 2004 | 110 | 0.180 |
Why?
| | Kidney Medulla | 3 | 2008 | 31 | 0.180 |
Why?
| | Epithelial Cells | 5 | 2012 | 1126 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-ets | 2 | 2012 | 56 | 0.170 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2002 | 561 | 0.160 |
Why?
| | Checklist | 1 | 2021 | 108 | 0.160 |
Why?
| | Interdisciplinary Communication | 1 | 2021 | 197 | 0.160 |
Why?
| | Cysts | 3 | 1995 | 111 | 0.150 |
Why?
| | Kidney Tubules, Proximal | 2 | 2012 | 130 | 0.150 |
Why?
| | Operating Rooms | 1 | 2021 | 146 | 0.150 |
Why?
| | Urologic Surgical Procedures, Male | 2 | 2011 | 32 | 0.150 |
Why?
| | Inflammation | 1 | 2010 | 2880 | 0.150 |
Why?
| | Urination | 1 | 2019 | 48 | 0.140 |
Why?
| | Hormone Replacement Therapy | 2 | 2013 | 106 | 0.140 |
Why?
| | Nephrectomy | 1 | 2019 | 158 | 0.140 |
Why?
| | Cell Survival | 4 | 2011 | 1098 | 0.140 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2010 | 266 | 0.140 |
Why?
| | Priapism | 1 | 1998 | 10 | 0.140 |
Why?
| | Administration, Intravesical | 1 | 2017 | 17 | 0.130 |
Why?
| | Patient Safety | 1 | 2021 | 349 | 0.130 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2011 | 259 | 0.130 |
Why?
| | Urethra | 1 | 2017 | 57 | 0.130 |
Why?
| | Neoplasm Invasiveness | 4 | 2012 | 509 | 0.130 |
Why?
| | Patient Care Team | 2 | 2021 | 689 | 0.130 |
Why?
| | Urinary Bladder, Overactive | 1 | 2017 | 23 | 0.130 |
Why?
| | Specimen Handling | 1 | 1998 | 186 | 0.130 |
Why?
| | Constriction, Pathologic | 4 | 2005 | 248 | 0.130 |
Why?
| | Kidney Tubules, Collecting | 2 | 2008 | 27 | 0.130 |
Why?
| | General Surgery | 1 | 2019 | 207 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 3 | 2008 | 138 | 0.120 |
Why?
| | Cell Line, Tumor | 8 | 2012 | 3550 | 0.120 |
Why?
| | Computer Communication Networks | 1 | 1996 | 32 | 0.120 |
Why?
| | Adult | 17 | 2022 | 40506 | 0.120 |
Why?
| | Muscle Contraction | 1 | 2019 | 429 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 3 | 2008 | 175 | 0.120 |
Why?
| | Animals | 15 | 2019 | 38109 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 357 | 0.110 |
Why?
| | Temperature | 1 | 1998 | 679 | 0.110 |
Why?
| | Internship and Residency | 2 | 2019 | 1257 | 0.110 |
Why?
| | Cannabinoids | 1 | 2017 | 182 | 0.110 |
Why?
| | Microsurgery | 2 | 2005 | 72 | 0.110 |
Why?
| | Wounds and Injuries | 1 | 2002 | 957 | 0.100 |
Why?
| | Opioid-Related Disorders | 1 | 2022 | 601 | 0.100 |
Why?
| | Drug Synergism | 2 | 2011 | 357 | 0.100 |
Why?
| | Marijuana Use | 1 | 2017 | 213 | 0.100 |
Why?
| | Asthenozoospermia | 1 | 2013 | 2 | 0.100 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1143 | 0.100 |
Why?
| | Imidazoles | 2 | 2011 | 254 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 4 | 2012 | 2540 | 0.090 |
Why?
| | Hyperoxaluria | 1 | 2012 | 3 | 0.090 |
Why?
| | Radiation-Protective Agents | 1 | 2012 | 17 | 0.090 |
Why?
| | Metalloporphyrins | 1 | 2012 | 66 | 0.090 |
Why?
| | Receptors, Virus | 1 | 2012 | 96 | 0.090 |
Why?
| | Rats | 5 | 2012 | 5614 | 0.090 |
Why?
| | Reproductive Techniques | 1 | 1991 | 5 | 0.090 |
Why?
| | Mitomycin | 1 | 2011 | 32 | 0.090 |
Why?
| | Valproic Acid | 1 | 2011 | 48 | 0.090 |
Why?
| | Radiotherapy | 1 | 2012 | 206 | 0.090 |
Why?
| | Osteoclasts | 1 | 2011 | 52 | 0.090 |
Why?
| | Cell Adhesion Molecules | 1 | 2012 | 178 | 0.090 |
Why?
| | Pediatrics | 1 | 2019 | 1115 | 0.080 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 68 | 0.080 |
Why?
| | Bone Resorption | 1 | 2011 | 80 | 0.080 |
Why?
| | Cell Hypoxia | 2 | 2009 | 247 | 0.080 |
Why?
| | Diabetes Complications | 2 | 2006 | 223 | 0.080 |
Why?
| | Patient Care Management | 1 | 2011 | 56 | 0.080 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2011 | 139 | 0.080 |
Why?
| | Laparoscopy | 2 | 2006 | 475 | 0.080 |
Why?
| | Androgens | 2 | 2009 | 186 | 0.080 |
Why?
| | Cell Movement | 2 | 2012 | 965 | 0.080 |
Why?
| | Resistance Training | 1 | 2013 | 182 | 0.080 |
Why?
| | Atrophy | 1 | 2010 | 201 | 0.080 |
Why?
| | Multicenter Studies as Topic | 1 | 2011 | 405 | 0.080 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 56 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 220 | 0.080 |
Why?
| | Membrane Glycoproteins | 1 | 2012 | 496 | 0.080 |
Why?
| | Neoplasm Seeding | 1 | 1989 | 7 | 0.080 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 286 | 0.080 |
Why?
| | Up-Regulation | 1 | 2012 | 852 | 0.070 |
Why?
| | Transfection | 2 | 2010 | 940 | 0.070 |
Why?
| | Prostatectomy | 1 | 1989 | 93 | 0.070 |
Why?
| | Biopsy, Needle | 1 | 1989 | 183 | 0.070 |
Why?
| | Bone Neoplasms | 1 | 2011 | 256 | 0.070 |
Why?
| | Antioxidants | 1 | 2012 | 549 | 0.070 |
Why?
| | Bone and Bones | 1 | 2011 | 315 | 0.070 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2008 | 35 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 292 | 0.070 |
Why?
| | Biopsy | 1 | 1992 | 1077 | 0.070 |
Why?
| | Prostatic Hyperplasia | 1 | 2008 | 40 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2008 | 621 | 0.070 |
Why?
| | Patient Selection | 1 | 2011 | 719 | 0.070 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2008 | 76 | 0.070 |
Why?
| | Bone Density | 1 | 2011 | 482 | 0.070 |
Why?
| | Ultrasonography | 4 | 1995 | 770 | 0.060 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2007 | 43 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2011 | 1054 | 0.060 |
Why?
| | Carcinoma in Situ | 1 | 2006 | 44 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2010 | 460 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 298 | 0.060 |
Why?
| | Oxidative Stress | 2 | 2010 | 1339 | 0.060 |
Why?
| | Acupuncture Therapy | 1 | 2006 | 21 | 0.060 |
Why?
| | Injections, Intralesional | 1 | 2006 | 36 | 0.060 |
Why?
| | Cell Line | 5 | 2012 | 2882 | 0.060 |
Why?
| | Computer Simulation | 1 | 2011 | 1026 | 0.060 |
Why?
| | Colonic Neoplasms | 1 | 1988 | 260 | 0.060 |
Why?
| | Health Resources | 1 | 2007 | 130 | 0.060 |
Why?
| | Biomarkers | 1 | 2017 | 4275 | 0.060 |
Why?
| | Anus, Imperforate | 1 | 2005 | 24 | 0.060 |
Why?
| | Software | 1 | 2011 | 692 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 142 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2609 | 0.060 |
Why?
| | Anastomosis, Surgical | 1 | 2006 | 157 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1786 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 375 | 0.060 |
Why?
| | Incidence | 2 | 2007 | 2883 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 557 | 0.060 |
Why?
| | Oxalic Acid | 1 | 2004 | 4 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1721 | 0.060 |
Why?
| | Rupture | 1 | 2004 | 91 | 0.050 |
Why?
| | Kidney | 1 | 2012 | 1496 | 0.050 |
Why?
| | Seminiferous Tubules | 1 | 2004 | 13 | 0.050 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2005 | 74 | 0.050 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2003 | 10 | 0.050 |
Why?
| | Signal Transduction | 3 | 2012 | 5233 | 0.050 |
Why?
| | Andrology | 1 | 2003 | 2 | 0.050 |
Why?
| | Sex Counseling | 1 | 2003 | 4 | 0.050 |
Why?
| | Hypoxia | 1 | 2010 | 1199 | 0.050 |
Why?
| | Female | 9 | 2021 | 78376 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2006 | 1371 | 0.050 |
Why?
| | Middle Aged | 7 | 2007 | 35928 | 0.050 |
Why?
| | Down-Regulation | 2 | 2017 | 627 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2007 | 603 | 0.050 |
Why?
| | Iatrogenic Disease | 1 | 2002 | 76 | 0.040 |
Why?
| | Adenocarcinoma | 1 | 1988 | 931 | 0.040 |
Why?
| | RNA, Small Interfering | 2 | 2017 | 635 | 0.040 |
Why?
| | Pain | 1 | 2006 | 782 | 0.040 |
Why?
| | Phenotype | 4 | 2010 | 3164 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2004 | 780 | 0.040 |
Why?
| | Adolescent | 4 | 2007 | 22453 | 0.040 |
Why?
| | Organizational Culture | 1 | 2021 | 162 | 0.040 |
Why?
| | Counseling | 1 | 2003 | 408 | 0.040 |
Why?
| | Aged | 6 | 2013 | 25947 | 0.040 |
Why?
| | Alcoholism | 1 | 2006 | 817 | 0.040 |
Why?
| | Sexual Behavior | 2 | 1994 | 492 | 0.040 |
Why?
| | Accreditation | 1 | 2019 | 101 | 0.040 |
Why?
| | Cell Growth Processes | 2 | 2010 | 50 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2007 | 8279 | 0.040 |
Why?
| | Cell Count | 2 | 2005 | 321 | 0.040 |
Why?
| | Mice | 5 | 2019 | 18365 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2011 | 2456 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2022 | 589 | 0.030 |
Why?
| | Risk Factors | 3 | 2002 | 10792 | 0.030 |
Why?
| | RNA, Messenger | 3 | 2012 | 2832 | 0.030 |
Why?
| | Caveolins | 1 | 2017 | 5 | 0.030 |
Why?
| | DNA Replication | 2 | 2004 | 251 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1718 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 5997 | 0.030 |
Why?
| | DNA Primers | 2 | 2010 | 512 | 0.030 |
Why?
| | Hospitalization | 1 | 2007 | 2434 | 0.030 |
Why?
| | Blotting, Western | 2 | 2010 | 1187 | 0.030 |
Why?
| | Seminal Vesicles | 1 | 1995 | 9 | 0.030 |
Why?
| | United States | 2 | 2019 | 15988 | 0.030 |
Why?
| | Prostatic Diseases | 1 | 1995 | 4 | 0.030 |
Why?
| | Arteries | 1 | 1998 | 259 | 0.030 |
Why?
| | Mullerian Ducts | 1 | 1995 | 17 | 0.030 |
Why?
| | Cytoskeleton | 1 | 2017 | 195 | 0.030 |
Why?
| | International Cooperation | 1 | 1996 | 198 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 1998 | 514 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 454 | 0.030 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2017 | 266 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2011 | 17101 | 0.030 |
Why?
| | Paternal Age | 1 | 1994 | 3 | 0.030 |
Why?
| | Climacteric | 1 | 1994 | 4 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 557 | 0.030 |
Why?
| | Skin | 2 | 2012 | 758 | 0.030 |
Why?
| | Rectum | 1 | 1995 | 180 | 0.030 |
Why?
| | Chromosome Disorders | 1 | 1994 | 45 | 0.030 |
Why?
| | Diverticulum | 1 | 1994 | 14 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 6053 | 0.030 |
Why?
| | Color | 1 | 1994 | 81 | 0.030 |
Why?
| | Base Sequence | 2 | 2010 | 2191 | 0.030 |
Why?
| | Urethral Diseases | 1 | 1994 | 18 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2005 | 6434 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 1994 | 163 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2022 | 1358 | 0.020 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 20 | 0.020 |
Why?
| | Leydig Cells | 1 | 1993 | 15 | 0.020 |
Why?
| | Gonadotropins, Pituitary | 1 | 1993 | 22 | 0.020 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2013 | 51 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 1994 | 529 | 0.020 |
Why?
| | Sertoli Cells | 1 | 1993 | 28 | 0.020 |
Why?
| | Gene Expression | 2 | 2008 | 1490 | 0.020 |
Why?
| | Physical Examination | 1 | 1994 | 240 | 0.020 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2012 | 41 | 0.020 |
Why?
| | Patient Dropouts | 1 | 2013 | 65 | 0.020 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2012 | 25 | 0.020 |
Why?
| | Sex Chromosome Aberrations | 1 | 1993 | 69 | 0.020 |
Why?
| | Quality Improvement | 1 | 2021 | 1291 | 0.020 |
Why?
| | Crystallization | 1 | 2012 | 146 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2012 | 87 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2012 | 194 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3125 | 0.020 |
Why?
| | Insemination, Artificial | 1 | 1991 | 11 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2012 | 252 | 0.020 |
Why?
| | Upper Extremity | 1 | 2013 | 112 | 0.020 |
Why?
| | Kidney Tubules | 1 | 2012 | 117 | 0.020 |
Why?
| | Pilot Projects | 1 | 2017 | 1890 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1995 | 1495 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2012 | 451 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 269 | 0.020 |
Why?
| | Menopause | 1 | 1994 | 320 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2013 | 233 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2012 | 521 | 0.020 |
Why?
| | Fertilization in Vitro | 1 | 1991 | 92 | 0.020 |
Why?
| | Efficiency | 1 | 2011 | 104 | 0.020 |
Why?
| | Mice, Nude | 1 | 2012 | 688 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 1195 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2012 | 220 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 862 | 0.020 |
Why?
| | Muscle Strength | 1 | 2013 | 330 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1268 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2011 | 919 | 0.020 |
Why?
| | Actuarial Analysis | 1 | 1989 | 21 | 0.020 |
Why?
| | Radiotherapy, High-Energy | 1 | 1989 | 18 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 695 | 0.020 |
Why?
| | DNA Damage | 1 | 2012 | 430 | 0.020 |
Why?
| | Activities of Daily Living | 1 | 2013 | 441 | 0.020 |
Why?
| | Workload | 1 | 2011 | 170 | 0.020 |
Why?
| | Safety | 1 | 2011 | 356 | 0.020 |
Why?
| | Body Composition | 1 | 2013 | 706 | 0.020 |
Why?
| | Tumor Stem Cell Assay | 1 | 2008 | 34 | 0.020 |
Why?
| | Patient Compliance | 1 | 2013 | 589 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1048 | 0.020 |
Why?
| | Anoikis | 1 | 2008 | 30 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 2032 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 1994 | 2118 | 0.020 |
Why?
| | Statistics as Topic | 1 | 1989 | 284 | 0.020 |
Why?
| | Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+) | 1 | 2008 | 7 | 0.020 |
Why?
| | Brachytherapy | 1 | 1989 | 134 | 0.020 |
Why?
| | Penile Erection | 1 | 2008 | 7 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 1989 | 334 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 983 | 0.020 |
Why?
| | Genes, Immediate-Early | 1 | 2008 | 26 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2008 | 75 | 0.020 |
Why?
| | Osmolar Concentration | 1 | 2008 | 167 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2008 | 55 | 0.020 |
Why?
| | Culture Media | 1 | 2008 | 161 | 0.020 |
Why?
| | Ureter | 1 | 1988 | 36 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2008 | 124 | 0.020 |
Why?
| | Lithotripsy | 1 | 1988 | 49 | 0.020 |
Why?
| | Cyclooxygenase 2 | 1 | 2008 | 165 | 0.020 |
Why?
| | Superoxides | 1 | 2008 | 204 | 0.020 |
Why?
| | Kidney Calculi | 1 | 1988 | 45 | 0.020 |
Why?
| | Catheters, Indwelling | 1 | 1988 | 96 | 0.020 |
Why?
| | Prevalence | 1 | 1994 | 2836 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2008 | 768 | 0.020 |
Why?
| | Regression Analysis | 1 | 1989 | 1003 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2008 | 311 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2008 | 455 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2008 | 337 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2008 | 167 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2008 | 336 | 0.020 |
Why?
| | Models, Animal | 1 | 2008 | 392 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1462 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 2008 | 263 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1496 | 0.010 |
Why?
| | Pyridines | 1 | 2010 | 605 | 0.010 |
Why?
| | Research Design | 1 | 2011 | 1137 | 0.010 |
Why?
| | Swine | 1 | 2008 | 833 | 0.010 |
Why?
| | Cell Cycle | 1 | 2008 | 597 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2925 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1054 | 0.010 |
Why?
| | Models, Biological | 1 | 2012 | 1822 | 0.010 |
Why?
| | Testicular Hydrocele | 1 | 2004 | 4 | 0.010 |
Why?
| | Urinary Retention | 1 | 2004 | 25 | 0.010 |
Why?
| | Ligation | 1 | 2004 | 92 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1742 | 0.010 |
Why?
| | Veins | 1 | 2004 | 68 | 0.010 |
Why?
| | Carcinoma | 1 | 1986 | 228 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1733 | 0.010 |
Why?
| | Pregnancy | 2 | 1997 | 7191 | 0.010 |
Why?
| | Algorithms | 1 | 2011 | 1839 | 0.010 |
Why?
| | Hospital Costs | 1 | 2004 | 124 | 0.010 |
Why?
| | Prognosis | 2 | 1989 | 4293 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3415 | 0.010 |
Why?
| | Drug Monitoring | 1 | 2006 | 395 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2008 | 11695 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2499 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2171 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 1098 | 0.010 |
Why?
| | Time Factors | 1 | 1989 | 7183 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2005 | 4155 | 0.010 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 1994 | 37 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2004 | 2920 | 0.010 |
Why?
| | Calcinosis | 1 | 1992 | 234 | 0.000 |
Why?
| | Silicones | 1 | 1988 | 29 | 0.000 |
Why?
| | Urinary Catheterization | 1 | 1988 | 33 | 0.000 |
Why?
| | Ureteral Obstruction | 1 | 1988 | 62 | 0.000 |
Why?
| | Child | 1 | 2004 | 22657 | 0.000 |
Why?
| | Neoplasm Recurrence, Local | 1 | 1986 | 1141 | 0.000 |
Why?
|
|
Meacham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|